Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of February 1, 2021:

Number of shares and voting rights of Innate Pharma as of February 1, 2021

MARSEILLE, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference:

Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit additional patients. The company expects to present the preliminary data from this cohort at a scientific meeting this year.

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated

Innate Pharma Advances Lacutamab Clinical Development Program

Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021

Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas

MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to progress IPH6101/SAR443579 into investigational new drug (IND)-enabling studies. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate's proprietary multispecific antibody format (Gauthier et al. Cell 2019 ).

Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

New York, New York--(Newsfile Corp. - December 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Innate securities between March 10, 2020 and September 8, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...

IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020

Investors with losses are encouraged to contact the firm before December 22, 2020; click here to submit trade information Investors with losses are encouraged to contact the firm before December 22, 2020; click here to submit trade information

Innate Pharma, S.A.: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

LOS ANGELES, Dec. 21, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innate Pharma S.A. ("Innate" or "the Company") (NASDAQ: IPHA) for violations of §§10(b) and 20(a) of the Securities...

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - December 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the "Class Period"), of the important December 22, 2020 lead plaintiff deadline in the securities class action first filed by the firm. The lawsuit seeks to recover damages for Innate investors under the federal securities...

IPHA FINAL DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Innate Pharma S.A. Investors of Important Tuesday Deadline in Securities Class Action - IPHA

New York, New York--(Newsfile Corp. - December 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the "Class Period"), of the important December 22, 2020 lead plaintiff deadline in the securities class action first filed by the firm. The lawsuit seeks to recover damages for Innate investors under the federal securities laws.To...

IPHA Deadline Alert: Rosen, A Trusted and Top Ranked Law Firm, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA

NEW YORK--(BUSINESS WIRE)-- #classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors that purchased Innate Pharma S.A. (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020 (the “Class Period”). Investors have until December 22, 2020 to apply to the Court to be appointed as lead plaintiff in th

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Innate Pharma S.A.

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (“Innate” or the "Company") (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On October 23, 2018, Innate and Astr

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the "Class Period"), of the important December 22, 2020 lead...

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA

BENSALEM, Pa., Dec. 14, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA ("Innate" or the...

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the “Class Period”).

Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHA

MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1. Innate licensed the US and EU rights to AstraZeneca's FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in October 2018.

Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca

Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1.  Innate licensed the US and EU rights to AstraZeneca's FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in October 2018 .

 Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca

New York, New York--(Newsfile Corp. - December 9, 2020) -   Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the "Class Period"), of the important December 22, 2020 lead plaintiff deadline in the securities class action first filed by the firm. The lawsuit seeks to recover damages for Innate investors under the federal securities...

Rosen, Trusted National Trial Counsel, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA

LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (“Innate” or the "Company") (NASDAQ: IPHA ) securities between March 10, 2020 and September 8, 2020, inclusive (the “Class Period”).

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws.

LOOMING DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Innate Pharma S.A. – IPHA

New York, New York--(Newsfile Corp. - December 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the "Class Period"), of the important December 22, 2020 lead plaintiff deadline in the securities class action first filed by the firm. The lawsuit seeks to recover damages for Innate investors under the federal securities laws.To...

Rosen, A Leading and Longstanding Law Firm, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action First Filed by Firm; Encourages Investors with Losses Exceeding $100K to Contact Firm - IPHA

Phase 2 expansion cohort data supports ongoing Phase 3 trial Phase 2 expansion cohort data supports ongoing Phase 3 trial

Innate Pharma to Present Additional Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ESMO Immuno-Oncology Virtual Congress

News for Innate Pharma SA Stock (IPHA)